Development of small-molecule inhibitors that target PI3Kβ

Yanzhen Yu,Dongyan Gu,Lvtao Cai,Haodong Yang,Rong Sheng

DOI: https://doi.org/10.1016/j.drudis.2023.103854

IF: 8.369

2024-01-01

Drug Discovery Today

Abstract:Phosphatidylinositol-3 kinase (PI3K) β, a subtype of class I PI3Ks, has an essential role in PTEN-deficient tumors and links to thrombosis, male fertility, and Fragile X syndrome. PI3Kβ-specific targeting therapy could be an efficacious treatment for diseases highly dependent on PI3Kβ, while mitigating the severe toxicity of pan-PI3K inhibitors. Achieving selectivity can be accomplished through three primary strategies, namely, binding to the induced lipophilic pocket, targeting the unique amino acid residue of PI3Kβ, or using atropisomerism to lock conformation. In this review, we focus on advances in the development of these β-isoform-selective PI3K inhibitors, providing potential guidance for the further development of novel clinical candidates.